decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
Appendix E - National Coverage Determinations Manual / COLLAGEN_CROSSLINKS
Subscribe or sign in to view the full article.
Article Overview
This page presents National Coverage Determinations Manual guidance on collagen crosslink testing, a laboratory assessment related to bone resorption and osteoporosis management. It explains the clinical background, the types of patients and treatment scenarios addressed, and the general utilization considerations that affect medical necessity and coverage. The article is useful for coders, billing staff, and clinicians working with osteoporosis-related laboratory testing and related Medicare policy.
Why This Topic Matters
Coverage policy for bone turnover testing can affect whether claims are payable and how follow-up testing is documented. Understanding the scope of this guidance helps teams align ordering, billing, and medical record support with Medicare policy expectations.
Article Sections
-
Collagen Crosslinks, Any Method
Introduces the coverage topic and provides the clinical background for collagen crosslink testing as a marker related to bone metabolism. It also describes the laboratory methods referenced in the policy context.
-
Indications
Summarizes the general patient populations and treatment scenarios addressed by the coverage guidance. The section focuses on the intended clinical uses of the test in osteoporosis-related care.
-
Limitations
Outlines utilization considerations and general restrictions discussed in the policy. It also notes that certain assay uses may be affected by FDA labeling restrictions.
What You Will Learn
- The clinical purpose of collagen crosslink testing in relation to bone turnover and osteoporosis.
- Which broad patient and treatment contexts are addressed by the coverage guidance.
- What general utilization limits and follow-up testing considerations are described in the policy.
- How the article frames this testing within Medicare coverage policy.
- What role FDA labeling restrictions may play in assay appropriateness.
Who Should Read This
- Medical coders
- Billing staff
- Compliance teams
- Clinicians managing osteoporosis care
- Laboratory and revenue cycle staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com